HROW vs. AVEO, KIN, LFVN, GERN, RYTM, BHC, DCPH, MRVI, VERA, and AMRX
Should you be buying Harrow stock or one of its competitors? The main competitors of Harrow include AVEO Pharmaceuticals (AVEO), Kindred Biosciences (KIN), LifeVantage (LFVN), Geron (GERN), Rhythm Pharmaceuticals (RYTM), Bausch Health Companies (BHC), Deciphera Pharmaceuticals (DCPH), Maravai LifeSciences (MRVI), Vera Therapeutics (VERA), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "medical" sector.
Harrow (NASDAQ:HROW) and AVEO Pharmaceuticals (NASDAQ:AVEO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
72.8% of Harrow shares are owned by institutional investors. Comparatively, 50.0% of AVEO Pharmaceuticals shares are owned by institutional investors. 13.7% of Harrow shares are owned by insiders. Comparatively, 3.3% of AVEO Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Harrow has a net margin of -22.59% compared to AVEO Pharmaceuticals' net margin of -30.79%. Harrow's return on equity of -39.82% beat AVEO Pharmaceuticals' return on equity.
AVEO Pharmaceuticals received 385 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 69.81% of users gave AVEO Pharmaceuticals an outperform vote while only 56.55% of users gave Harrow an outperform vote.
In the previous week, Harrow had 8 more articles in the media than AVEO Pharmaceuticals. MarketBeat recorded 8 mentions for Harrow and 0 mentions for AVEO Pharmaceuticals. Harrow's average media sentiment score of 0.77 beat AVEO Pharmaceuticals' score of 0.25 indicating that Harrow is being referred to more favorably in the media.
Harrow has higher revenue and earnings than AVEO Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than AVEO Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Harrow currently has a consensus target price of $28.60, indicating a potential upside of 57.40%. Given Harrow's higher probable upside, equities analysts plainly believe Harrow is more favorable than AVEO Pharmaceuticals.
Harrow has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
Summary
Harrow beats AVEO Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Harrow News Delivered to You Automatically
Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
